Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

224 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II trial of prophylactic olanzapine combined with palonosetron and dexamethasone for preventing nausea and vomiting induced by cisplatin.
Maeda A, Ura T, Asano C, Haegawa I, Nomura M, Komori A, Narita Y, Taniguchi H, Kadowaki S, Muro K, Horio Y, Yoshida T, Oze I, Kajita M, Mizutani A. Maeda A, et al. Among authors: oze i. Asia Pac J Clin Oncol. 2016 Sep;12(3):254-8. doi: 10.1111/ajco.12489. Epub 2016 Mar 31. Asia Pac J Clin Oncol. 2016. PMID: 27030364 Clinical Trial.
Randomized phase II study comparing dose escalated weekly paclitaxel vs. standard dose weekly paclitaxel for patients with previously treated advanced gastric cancer.
Shitara K, Oze I, Mizota A, Kondo C, Nomura M, Yokota T, Takahari D, Ura T, Yuki S, Komatsu Y, Matsuo K, Muro K. Shitara K, et al. Among authors: oze i. Jpn J Clin Oncol. 2011 Feb;41(2):287-90. doi: 10.1093/jjco/hyq206. Epub 2010 Nov 9. Jpn J Clin Oncol. 2011. PMID: 21068025 Clinical Trial.
Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer.
Shitara K, Yuki S, Tahahari D, Nakamura M, Kondo C, Tsuda T, Kii T, Tsuji Y, Utsunomiya S, Ichikawa D, Hosokawa A, Ishiguro A, Sakai D, Hironaka S, Oze I, Matsuo K, Muro K. Shitara K, et al. Among authors: oze i. Br J Cancer. 2014 Jan 21;110(2):271-7. doi: 10.1038/bjc.2013.726. Epub 2013 Nov 26. Br J Cancer. 2014. PMID: 24281004 Free PMC article. Clinical Trial.
Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis.
Nomura M, Oze I, Abe T, Komori A, Narita Y, Masuishi T, Taniguchi H, Kadowaki S, Ura T, Andoh M, Kawai R, Uemura N, Ishihara M, Tanaka T, Tajika M, Niwa Y, Muro K, Muto M. Nomura M, et al. Among authors: oze i. Cancer Chemother Pharmacol. 2015 Aug;76(2):357-63. doi: 10.1007/s00280-015-2806-8. Epub 2015 Jun 20. Cancer Chemother Pharmacol. 2015. PMID: 26092324
Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis.
Nomura M, Oze I, Kodaira T, Abe T, Komori A, Narita Y, Masuishi T, Taniguchi H, Kadowaki S, Ura T, Andoh M, Tachibana H, Uemura N, Tajika M, Niwa Y, Muto M, Muro K. Nomura M, et al. Among authors: oze i. Int J Clin Oncol. 2016 Oct;21(5):890-898. doi: 10.1007/s10147-016-0963-3. Epub 2016 Mar 15. Int J Clin Oncol. 2016. PMID: 26980212
A phase I/II trial of weekly nab-paclitaxel for pretreated non-small-cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement.
Harada D, Kozuki T, Nogami N, Bessho A, Hosokawa S, Fukamatsu N, Hotta K, Ohashi K, Kubo T, Yoshioka H, Yokoyama T, Sone N, Kuyama S, Kudo K, Yasugi M, Takigawa N, Oze I, Kiura K. Harada D, et al. Among authors: oze i. Asia Pac J Clin Oncol. 2019 Aug;15(4):250-256. doi: 10.1111/ajco.13147. Epub 2019 Apr 1. Asia Pac J Clin Oncol. 2019. PMID: 30938103 Free PMC article. Clinical Trial.
224 results